Truist Securities Reiterates Hookipa Pharma (HOOK) Buy Recommendation
Fintel reports that on September 6, 2023, Truist Securities reiterated coverage of Hookipa Pharma (NASDAQ:HOOK) with a Buy recommendation.
Analyst Price Forecast Suggests 531.96% Upside
As of August 31, 2023, the average one-year price target for Hookipa Pharma is 4.37. The forecasts range from a low of 0.50 to a high of $7.35. The average price target represents an increase of 531.96% from its latest reported closing price of 0.69.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Hookipa Pharma is 18MM, an increase of 11.23%. The projected annual non-GAAP EPS is -0.98.
What is the Fund Sentiment?
There are 79 funds or institutions reporting positions in Hookipa Pharma. This is an increase of 7 owner(s) or 9.72% in the last quarter. Average portfolio weight of all funds dedicated to HOOK is 0.08%, an increase of 651.01%. Total shares owned by institutions increased in the last three months by 98.07% to 46,704K shares. 
The put/call ratio of HOOK is 0.23, indicating a bullish outlook.
What are Other Shareholders Doing?
Artal Group holds 5,666K shares representing 6.75% ownership of the company. In it's prior filing, the firm reported owning 1,850K shares, representing an increase of 67.36%. The firm increased its portfolio allocation in HOOK by 92.17% over the last quarter.
Knoll Capital Management holds 5,517K shares representing 6.57% ownership of the company. In it's prior filing, the firm reported owning 300K shares, representing an increase of 94.56%. The firm increased its portfolio allocation in HOOK by 1,629.71% over the last quarter.
EcoR1 Capital holds 4,595K shares representing 5.47% ownership of the company. In it's prior filing, the firm reported owning 2,473K shares, representing an increase of 46.17%. The firm increased its portfolio allocation in HOOK by 69.00% over the last quarter.
Baker Bros. Advisors holds 4,426K shares representing 5.27% ownership of the company. In it's prior filing, the firm reported owning 3,476K shares, representing an increase of 21.47%. The firm increased its portfolio allocation in HOOK by 61.94% over the last quarter.
Armistice Capital holds 3,856K shares representing 4.59% ownership of the company.
Hookipa Pharma Background Information
(This description is provided by the company.)
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.
Additional reading:
- HOOKIPA PHARMA INC. 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 NEW YORK, NEW YORK 10118 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS August 10, 2023 HOOKIPA PHARMA INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTI
- FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE PARTICIPANTS
- Form of Announcement Email to All Employees
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.